eplex sars-cov-2 diagnostic test (GenMark Diagnostics)
90
Structured Review
GenMark Diagnostics
eplex sars-cov-2 diagnostic test
Eplex Sars Cov 2 Diagnostic Test, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eplex+sars-cov-2/eplex+sars+cov+2+test/pm40386630-56-9-9
Average 90 stars, based on 1 article reviews
Eplex Sars Cov 2 Diagnostic Test, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eplex+sars-cov-2/eplex+sars+cov+2+test/pm40386630-56-9-9
Average 90 stars, based on 1 article reviews
eplex sars-cov-2 diagnostic test - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Amplification:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Reverse Transcription Polymerase Chain Reaction:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Fluorescence:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Control:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Luminex:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Virus:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Real-time Polymerase Chain Reaction:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the CDC Assay:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Quantitative RT-PCR:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Comparison:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Biomarker Discovery:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Reverse Transcription:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Diagnostic Assay:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the Infection:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the CRISPR:Article Title: Strategies for Scaling up SARS-CoV-2 Molecular Testing Capacity Article Snippet: Hologic Panther Fusion SARS-CoV-2 Assay (Fusion) Simplexa COVID-19 Direct (Diasorin) Article Title: Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages Article Snippet: Article Title: Challenges in Urology during the COVID-19 Pandemic Article Snippet: ePlex SARS-CoV-2 , Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: GenMark Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Article Title: An Overview of SARS-CoV-2 Molecular Diagnostics in Europe Article Snippet: Several platforms fail to achieve the MHRA TPP “acceptable” LOD criteria of 1000 copies/ml; GenomEra SARS-CoV-2, Flu A/B+ RSV at 2857 copies/mL, Novodiag COVID-19 at 1815 copies/mL when using collection devices other than the provided medium nucleic acid amplification test; and both the |